Voyager Therapeutics Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference

CAMBRIDGE, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. VYGR announced today the cancellation of the Company's presentation and webcast at the Barclays Global Healthcare Conference, previously scheduled to take place on March 10, 2020 at 4:20 p.m. ET. The change follows the cancellation of the in-person aspects of the conference by the organizer given the current COVID-19 circumstances. The Company will still hold scheduled investor meetings via conference call.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager's wholly-owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson's disease, Huntington's disease, a monogenic form of ALS called SOD1, Friedreich's ataxia, Alzheimer's disease, and other neurodegenerative diseases related to defective or excess aggregation of tau and alpha-synuclein proteins in the brain. Voyager has strategic collaborations with AbbVie and Neurocrine Biosciences. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.

Investors:       
Paul Cox
VP, Investor Relations
857-201-3463
pcox@vygr.com

Media:
Sheryl Seapy
W2Opure
949-903-4750
sseapy@purecommunications.com